Mucopolysaccharidosis, often abbreviated MPS, refers to a family of inherited lysosomal storage disorders rather than a single condition. Several recognized subtypes have been described, including MPS I, MPS II, MPS III, MPS IV, MPS VI, MPS VII, and MPS IX. Each subtype reflects a different enzyme deficiency, and the specific enzyme that is missing or reduced determines which complex sugar molecules build up inside cells, which organs are most affected, and how the condition typically progresses. Despite these differences, the subtypes share a common biological mechanism. In healthy cells, lysosomes act as recycling centers that break down long sugar chains called glycosaminoglycans, which were historically called mucopolysaccharides. When a specific lysosomal enzyme does not work properly, these sugar chains accumulate inside lysosomes throughout the body and disrupt the normal function of multiple tissues. Because mucopolysaccharidosis is an umbrella term, a person is generally diagnosed with a specific subtype rather than with mucopolysaccharidosis in general, and clinical care, prognosis, and eligibility for targeted therapies depend on which subtype is present.

Because mucopolysaccharidosis includes several distinct subtypes, the pattern of features can vary considerably from one person to another, and even between people who share the same subtype. Some forms primarily affect the skeleton and connective tissues, others have more pronounced effects on the brain and nervous system, and still others involve a combination of systemic findings. Skeletal and joint findings can include short stature, joint stiffness or limited range of motion, spinal changes, and a characteristic constellation of bone abnormalities sometimes called dysostosis multiplex on imaging. Facial features may become more prominent over time in certain subtypes. Eye involvement can include corneal clouding in some subtypes, and the inner ear may be affected, leading to hearing differences. The heart can show valve thickening or other structural changes, and the liver and spleen may be enlarged. The respiratory system can be affected through narrowing of the airways and recurrent infections. In several subtypes, particularly the more severe forms, the central nervous system can be involved and may lead to developmental differences, learning challenges, or progressive neurologic features. Onset and trajectory differ widely. Some subtypes present in infancy with rapidly evolving features, while others become apparent later in childhood or adolescence and progress more slowly. Not all individuals experience all features, and severity varies considerably.

Mucopolysaccharidosis results from changes in several different genes, and the specific gene involved depends on the subtype. Because the gene-level information was not fully populated for the umbrella entry in this dataset, this summary does not name individual causative genes. In general, each subtype is caused by reduced or absent activity of a specific lysosomal enzyme that is needed to break down a particular type of glycosaminoglycan. Inheritance patterns differ by subtype. Most forms of mucopolysaccharidosis are inherited in an autosomal recessive pattern, which means that a child typically develops the condition when both copies of the relevant gene carry a disease-causing change, and parents who each carry a single copy usually do not have symptoms themselves. Mucopolysaccharidosis type II, also called Hunter syndrome, is the notable exception and follows an X-linked inheritance pattern, which has different implications for who is affected and for recurrence in families. Recurrence risk and family planning conversations are most accurate when they are tied to the specific subtype identified in a given family. Genetic counseling can help families understand the inheritance pattern that applies to their situation.

Diagnosis usually begins when a clinician notices a pattern of features across several organ systems that together raise suspicion for a lysosomal storage disorder. Symptoms can overlap with other conditions, and because each MPS subtype has a different enzyme deficiency, confirming both the broad category and the specific subtype is important. Initial evaluation typically combines a careful clinical examination, growth and developmental assessment, and imaging of the skeleton, abdomen, and heart when indicated. Laboratory testing often includes measurement of urinary glycosaminoglycans, which can suggest excessive storage, followed by enzyme activity testing in blood or skin cells to identify which specific enzyme is reduced. Molecular genetic testing of the gene that codes for the deficient enzyme is then used to confirm the diagnosis at the DNA level. Newborn screening for some MPS subtypes is now available in parts of the United States and other regions, which can allow earlier identification before symptoms become prominent. Evaluation is generally coordinated through a metabolic or genetics specialist, often working with subspecialists in cardiology, orthopedics, neurology, and ophthalmology.

Treatment for mucopolysaccharidosis is highly subtype-specific, and eligibility for any targeted therapy depends on the exact MPS type a person has. Foundational care is similar across the family of conditions and centers on supportive and multidisciplinary management. This includes monitoring of growth, hearing, vision, cardiac function, airway and respiratory status, and skeletal alignment, along with physical and occupational therapy, pain management, and surgical interventions when needed. Several enzyme replacement therapies have been approved by the FDA for specific MPS subtypes. Idursulfase, sold as Elaprase, is approved as long-term enzyme replacement therapy for mucopolysaccharidosis II, also called Hunter syndrome. N-acetylgalactosamine-4-sulfatase, marketed as Naglazyme, is approved for mucopolysaccharidosis VI, also called Maroteaux-Lamy syndrome. Vestronidase alfa-vjbk, sold as Mepsevii, is approved for mucopolysaccharidosis VII, also called Sly syndrome. Each of these therapies is intended only for the specific subtype listed. Hematopoietic stem cell transplantation has been used for certain MPS subtypes when central nervous system involvement is a concern, and the decision to pursue transplant is highly individualized. Several gene therapy programs targeting specific subtypes have received orphan drug designation and remain investigational. Regular surveillance is an essential part of long-term care.

Outcomes in mucopolysaccharidosis depend strongly on which subtype a person has, how early the diagnosis is made, and which organ systems are most affected. Some subtypes are characterized by progressive multisystem involvement that can significantly shorten life expectancy, while other subtypes follow a more attenuated course in which adults can live for many decades with appropriate medical care. Even within a single subtype, the trajectory can range from a more severe early-onset form to a more slowly progressing later-onset form. Outcomes have been improving over time as awareness of the condition grows, as enzyme replacement therapies become more widely available for the subtypes that have approved options, and as multidisciplinary care models help anticipate and manage complications. Long-term outlook conversations are most useful when they are grounded in the specific subtype and the individual person's clinical features rather than in mucopolysaccharidosis as a whole.

Research in mucopolysaccharidosis is active across the family of conditions. Numerous clinical studies are underway that span enzyme replacement strategies, biologic therapies, and gene therapy programs targeting specific subtypes, and several investigations focus on natural history and biomarkers that can help measure how the conditions evolve and how they respond to treatment. Sponsorship is mixed across academic groups and pharmaceutical companies. Published research output has also been substantial, with a notable share of work focused on basic and preclinical science alongside reports from recent trials. Individuals interested in clinical trials can search ClinicalTrials.gov or consult their care team to understand which studies are open for the specific subtype involved and whether participation may be appropriate.